ArticleInternational journal of clinical oncology2025
Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsStandard treatments for locally advanced oropharyngeal cancer (OPC) include surgery and chemoradiotherapy (CRT). While surgery offers good tumor control, it often results in significant postoperative functional impairments. Conversely, intravenous chemoradiotherapy (IV-CRT) is less effective in controlling primary tumors in T4 OPC cases and offers limited options for salvage surgery after recurrence. RADPLAT, a treatment involving intra-arterial cisplatin combined with radiotherapy, has demonstrated favorable results for other cancers and may offer an alternative treatment for OPC.
methodsThis retrospective study compared the efficacy and safety of RADPLAT and IV-CRT in the patients with T4 OPC treated at Hokkaido University Hospital between 2003 and 2022. The primary endpoint was local recurrence-free survival (LRFS), and the secondary endpoint was overall survival (OS).
resultsFifty-six patients were included, with 29 in the RADPLAT group and 27 in the IV-CRT group. The RADPLAT group showed significantly better LRFS (2-year LRFS: 82.3%) and OS (5-year OS: 73.8%) compared to the IV-CRT group (2y-LRFS: 66.0%, 5y-OS: 45.7%). Multivariate analysis identified RADPLAT as an independent favorable prognostic factor for both LRFS and OS. There was no significant difference in the incidence of adverse events between the two groups, although grade 3 or higher mucositis was more common in the RADPLAT group. Swallowing function and tracheostomy rates were similar between the groups.
conclusionRADPLAT provides superior local control and survival outcomes compared to IV-CRT for T4 OPC, with comparable safety and functional preservation. These findings suggest that RADPLAT may be a promising alternative to IV-CRT for cases with T4 OPC.
Indexed as
Identifiers
40146381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.